Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoshiki Hata

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
ESC Heart Failure|March 10, 2022
Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fractionMitsutaka Nakashima, Toru Miyoshi, Kentaro Ejiri, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|March 12, 2010
Elevated oxidative stress is associated with ventricular fibrillation episodes in patients with Brugada-type electrocardiogram without SCN5A mutationMasamichi Tanaka, Kazufumi Nakamura, Kengo Fukushima Kusano, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|April 24, 2026
Esaxerenone versus angiotensin II receptor blockers as second-line therapy in older Japanese patients with uncontrolled hypertension on calcium channel blockers: the randomized, open-label ESCORT-HT studyKazuomi Kario, Hiroyuki Ohbayashi, Hajime Ishii, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|November 9, 2020
Monotherapy With Prasugrel After Dual-Antiplatelet Therapy for Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk - A Prospective Cohort Study (PENDULUM mono Study)Masato Nakamura, Yoshihiro Morino, Tsunekazu Kakuta, et al.
Cardiovascular Intervention and Therapeutics|November 13, 2020
Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2Hirotoshi Watanabe, Takeshi Morimoto, Manabu Ogita, et al.
Journal of the American College of Cardiology|October 25, 2023
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary InterventionHirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, et al.
The American Journal of Cardiology|September 3, 2023
SYNTAX Score and 1-Year Outcomes in the OPTIVUS-Complex PCI Study Multivessel CohortMasaomi Gohbara, Kiyoshi Hibi, Takeshi Morimoto, et al.
Cardiovascular Intervention and Therapeutics|April 6, 2025
Complex PCI and 1-year outcomes in the OPTIVUS-complex PCI study multivessel cohortMasaomi Gohbara, Kiyoshi Hibi, Takeshi Morimoto, et al.
JAMA|June 26, 2019
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical TrialHirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
Circulation. Cardiovascular Interventions|August 1, 2022
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total CohortYuki Obayashi, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
ESC Heart Failure|March 10, 2022
Effects of luseogliflozin on estimated plasma volume in patients with heart failure with preserved ejection fractionMitsutaka Nakashima, Toru Miyoshi, Kentaro Ejiri, et al.
Cardiovascular Pathology : the Official Journal of the Society for Cardiovascular Pathology|March 12, 2010
Elevated oxidative stress is associated with ventricular fibrillation episodes in patients with Brugada-type electrocardiogram without SCN5A mutationMasamichi Tanaka, Kazufumi Nakamura, Kengo Fukushima Kusano, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|April 24, 2026
Esaxerenone versus angiotensin II receptor blockers as second-line therapy in older Japanese patients with uncontrolled hypertension on calcium channel blockers: the randomized, open-label ESCORT-HT studyKazuomi Kario, Hiroyuki Ohbayashi, Hajime Ishii, et al.
Circulation Journal : Official Journal of the Japanese Circulation Society|November 9, 2020
Monotherapy With Prasugrel After Dual-Antiplatelet Therapy for Japanese Percutaneous Coronary Intervention Patients With High Bleeding Risk - A Prospective Cohort Study (PENDULUM mono Study)Masato Nakamura, Yoshihiro Morino, Tsunekazu Kakuta, et al.
Cardiovascular Intervention and Therapeutics|November 13, 2020
Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2Hirotoshi Watanabe, Takeshi Morimoto, Manabu Ogita, et al.
Journal of the American College of Cardiology|October 25, 2023
Clopidogrel vs Aspirin Monotherapy Beyond 1 Year After Percutaneous Coronary InterventionHirotoshi Watanabe, Takeshi Morimoto, Masahiro Natsuaki, et al.
The American Journal of Cardiology|September 3, 2023
SYNTAX Score and 1-Year Outcomes in the OPTIVUS-Complex PCI Study Multivessel CohortMasaomi Gohbara, Kiyoshi Hibi, Takeshi Morimoto, et al.
Cardiovascular Intervention and Therapeutics|April 6, 2025
Complex PCI and 1-year outcomes in the OPTIVUS-complex PCI study multivessel cohortMasaomi Gohbara, Kiyoshi Hibi, Takeshi Morimoto, et al.
JAMA|June 26, 2019
Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical TrialHirotoshi Watanabe, Takenori Domei, Takeshi Morimoto, et al.
Circulation. Cardiovascular Interventions|August 1, 2022
Clopidogrel Monotherapy After 1-Month Dual Antiplatelet Therapy in Percutaneous Coronary Intervention: From the STOPDAPT-2 Total CohortYuki Obayashi, Hirotoshi Watanabe, Takeshi Morimoto, et al.
Pageof 4